GSK (LON:GSK) PT Lowered to GBX 1,850

GSK (LON:GSK) had its target price reduced by equities researchers at Deutsche Bank Aktiengesellschaft from GBX 1,950 ($25.08) to GBX 1,850 ($23.80) in a research note issued on Wednesday, Digital Look reports. The brokerage presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential upside of 22.80% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 ($27.01) target price on shares of GSK in a research report on Thursday, June 27th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Monday. Barclays restated an “equal weight” rating and set a GBX 1,725 ($22.19) target price on shares of GSK in a report on Tuesday, May 7th. Citigroup cut their target price on GSK from GBX 2,120 ($27.27) to GBX 1,900 ($24.44) and set a “buy” rating on the stock in a report on Friday, July 5th. Finally, Shore Capital restated a “buy” rating on shares of GSK in a report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of GBX 1,805.71 ($23.23).

GSK Stock Performance

Shares of GSK stock opened at GBX 1,506.50 ($19.38) on Wednesday. The stock has a market cap of £61.47 billion, a PE ratio of 1,382.11, a price-to-earnings-growth ratio of 1.19 and a beta of 0.27. The business has a fifty day simple moving average of GBX 1,586.30 and a 200-day simple moving average of GBX 1,636.22. The company has a quick ratio of 0.73, a current ratio of 0.87 and a debt-to-equity ratio of 134.34. GSK has a 12 month low of GBX 1,330.19 ($17.11) and a 12 month high of GBX 1,823.50 ($23.46).

Insider Activity

In other news, insider Wendy Becker bought 446 shares of the company’s stock in a transaction dated Thursday, June 20th. The stock was bought at an average price of GBX 1,614 ($20.76) per share, with a total value of £7,198.44 ($9,259.63). 1.60% of the stock is currently owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.